Streetwise Reports' Article Archives — November 2020 back to current month (28)
Novavax Shares Get a Boost from Developments at Three Separate COVID-19 Vaccine Trials (11/30/2020)
Novavax shares traded 11% higher after the company finalized enrollment in two advanced COVID-19 vaccine clinical trials with a third one slated to commence in the coming weeks.
Rhythm Pharma Earns FDA Approval for Chronic Weight Management Drug for Rare Genetic Obesity Diseases (11/27/2020)
Shares of Rhythm Pharmaceuticals traded 25% higher after the FDA granted approval of IMCIVREE™ (setmelanotide) as the first-ever therapy for chronic weight management in patients with obesity due to POMC, PCSK1 or LEPR deficiency.
Pharma Developer Raises Enrollment Goal for Multinational Phase 2b/3 COVID-19 Trial (11/25/2020)
Algernon Pharmaceuticals reported it has enrolled 154 patients in its Phase 2b/3 human study of Ifenprodil for COVID-19 and is increasing the pool to 168 patients to allow for attrition.
Biopharma Targeting Glioblastoma Multiforme Commences Clinical Program (11/25/2020)
Preclinical results for Black Diamond Therapeutics' kinase inhibitor, BDTX-1535, are reviewed in an H.C. Wainwright & Co. report.
U.S. Biopharma Expands Into ALS, Doses First Patient in 'Potentially Pivotal' Trial (11/25/2020)
The design of Apellis Pharmaceuticals and its partner's clinical study is presented in a ROTH Capital Partners report.
Renalytix AI Shares Climb 30% on Q1 Earnings and EUA for JV's SARS-CoV-2 IgG Antibody Test Kit (11/25/2020)
Shares of Renalytix AI Plc. traded 30% higher after the company reported Q1/21 financial results and that its joint venture with Mt. Sinai Health System was granted Emergency Use Authorization by the FDA for its SARS-CoV-2 IgG antibody test kit.
Biotech Collaborates to Advance Psychedelics Use in Cancer, Other Applications (11/23/2020)
Revive Therapeutics enters an agreement with PharmaTher, a specialty psychedelics pharmaceutical firm.
Precision BioSciences & Eli Lilly Partner to Develop In Vivo Therapies for Genetic Disorders (11/20/2020)
Precision BioSciences shares traded 13% higher after the company reported it is partnering with Eli Lilly & Co. to develop in vivo therapies for genetic disorders with an initial focus on Duchenne's muscular dystrophy and two other undisclosed gene targets.
Corcept Therapeutics Shares Rise 25% on Favorable U.S. Patent Office Ruling (11/19/2020)
Shares of Corcept Therapeutics reached a new 52-week high after the firm reported that the U.S. Patent Trial and Appeals Board affirmed that all claims pertaining to its U.S. Patent No.10,195,214 are valid.
Kodiak Sciences Announces Pricing of $560.9 Million Common Stock Offering (11/18/2020)
Kodiak Sciences shares reached a new 52-week high after the company announced the pricing of a $560.9 million public offering of its common stock. The report came one day after the firm advised it had completed enrollment of its Phase 2b/3 Pivotal DAZZLE Study of KSI-301 in patients with wet age-related macular degeneration.
Lexicon Shares Rise 40% upon Achieving Primary Endpoints in Two Phase 3 Heart Failure Studies (11/17/2020)
Shares of Lexicon Pharmaceuticals traded higher after the company published results from the Phase 3 SOLOIST and SCORED trials showing that sotagliflozin significantly reduced total cardiovascular deaths, heart failure hospitalization and urgent visits.
Psychedelic Company Expected to Begin Trading Nov. 18 (11/17/2020)
Delic Corp., a thought leader in psychedelics, will trade on the Canadian Securities Exchange.
Moderna Shares Get a Boost from Phase 3 COVID-19 Vaccine Trial Data Demonstrating 94.5% Efficacy (11/16/2020)
Moderna shares traded 10% higher to a new 52-week high after the company reported its COVID-19 vaccine candidate, mRNA-1273, met its primary endpoint in the first interim analysis of the Phase 3 COVE Study by achieving an efficacy rate of 94.5%.
Life Sciences Firm Completes Development of Dissolvable Oral Psilocybin (11/14/2020)
Revive Therapeutics reported that it has developed an oral thin-film strip psilocybin product with doses ranging from 1 to 20 milligrams.
Urovant Sciences Shares Double on Sumitovant Biopharma Buyout Offer (11/13/2020)
Shares of Urovant Sciences traded 93% higher to a new 52-week high after the company reported that it entered into a definitive agreement to be acquired by Sumitovant Biopharma for $16.25 per share in cash.
Biotech Involved in COVID-19, Neurodegenerative Diseases Reports Q3/20 Results (11/12/2020)
ProMIS Neurosciences formed two new joint ventures, one for developing tests for the detection, diagnosis and monitoring of Alzheimer's disease, and the second for serological assays for antibodies to the SARS-CoV-2 virus.
Biotech Comments on FDA Advisory Committee Recommendation of Not Licensing Alzheimer's Drug (11/11/2020)
ProMIS Neurosciences, which is developing its own therapeutics for this disease, weighs in on the committee's conclusions regarding Biogen's aducanumab.
Biotech Plans to Release Interim Data for Phase 2b/3 COVID-19 Trial in December (11/11/2020)
Algernon Pharmaceuticals reported it intends to announce the interim results from its Ifenprodil Phase 2b/3 COVID-19 human study during the first week of December 2020.
Biopharma Posts 'Impressive' Q3/20 Sales Amid Pandemic (11/11/2020)
Paratek Pharmaceuticals' recent and future revenue are discussed in an H.C. Wainwright & Co. report.
Five Prime Shares Triple in Value as Firm Meets All 3 Primary Endpoints in Phase 2 Gastric and GEJ Cancer Trial (11/11/2020)
Five Prime Therapeutics shares traded 250% higher after the firm reported topline data from its Phase 2 FIGHT study of bemarituzumab in combination with chemotherapy demonstrated significant progression-free and overall survival rates in advanced gastric and gastroesophageal junction cancer.
Individuals Succeed Using This Digital Therapy—Now It's Moving to Insurers (11/10/2020)
Independent financial analyst Matt Badiali profiles a digital therapeutics company that is changing diabetes treatment.
Pfizer shares traded 9% higher to a new 52-week high after the company reported that interim data from its Phase 3 COVID-19 vaccine trial with BioNTech showed a 90% success rate in participants without prior evidence of SARS-CoV-2 infection. The company is making plans to produce up to 1.3 billion vaccine doses in 2021.
Draganfly Screening Technology Battles Campus, Public Facilities Health Challenges (11/09/2020)
Knox Henderson delves into how Draganfly's cutting-edge technology is making it possible for universities and other organizations to operate safely during the pandemic.
Glaukos Shares Pressured Higher After Firm Reports 11% Rise in Q3 Revenue (11/06/2020)
Shares of Glaukos Corp. traded 9% higher after the company reported Q3/20 financial results that included an 11% YoY increase in glaucoma and corneal health net sales.
U.S. Biotech Developing Cancer Therapeutics Has 'Deep Pipeline' (11/04/2020)
ImmunoGen's broad pipeline that "could support long-term growth" is discussed in an H.C. Wainwright & Co. report.
Supernus Pharma Shares Trade Up 21% on 52% Increase in Q3 YoY Revenue (11/04/2020)
Shares of Supernus Pharmaceuticals traded higher after the company reported financial results for Q3/20 that included a 52% increase in total revenues versus the same period in 2019.
Inspire Medical's Shareholders Rest Comfortably on Q3 Earnings and Raised FY Outlook (11/03/2020)
Shares of Inspire Medical Systems traded 30% higher and set a new 52-week high after the company reported Q3/20 financial results that included a 72% rise in YoY revenue.
Multinational Phase 2b/3 COVID-19 Study Approved to Continue (11/02/2020)
Two doses of Algernon Pharmaceuticals' NP-120, or Ifenprodil, are being tested for safety and efficacy.
More Archives
2024Nov Oct Sep Aug Jul Jun May Apr Mar Feb Jan
2023Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2022Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2021Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
